Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
Related Questions
What testing do you utilize to decide a patient's candidacy for Resmetirom therapy?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
What are your biggest takeaways from the MASH-TAG 2025 conference?
How do you approach a patient with discordant Fibroscan and serologic testing for fibrosis?
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
How do you diagnose cystic fibrosis related liver disease?
What is your approach to the management of anti-pruritic therapies in patients with cholestatic liver disease?
What management considerations do you keep in mind in the management of pregnant patients with autoimmune liver disease?
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
How do you approach fertility/family planning and counseling in patients with end-stage liver disease?
